Recombinant Human IL-6

Background

IL6 is a pleiotropic cytokine involved in regulating immune responses, inflammation, and hematopoiesis It is produced by macrophages, T cells, fibroblasts, and endothelial cells in response to infections, trauma, or tissue damage IL6 activates downstream signaling through its receptor, IL-6R, and the JAK/STAT3 pathway, driving acute-phase protein synthesis, such as CRP and fibrinogen, and promoting B cell differentiation into plasma cells Dysregulated IL6 expression is associated with chronic inflammation, autoimmune diseases like rheumatoid arthritis, and cancer progression, where it promotes tumor growth, survival, and angiogenesis IL6 also contributes to cytokine storm syndrome in conditions like COVID-19, where excessive IL6 leads to hyperinflammation and organ damage Targeting IL6 signaling with anti-IL6 therapies, such as tocilizumab, has shown efficacy in treating autoimmune diseases and cytokine-driven conditions